Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCX 470 vs. Latanoprost in Open-Angle Glaucoma or Ocular Hypertension
NCT04445519Phase 3Completed
- Sponsor
- Nicox S.A.
- Start
- Jun 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of NCX 470 in open-angle glaucoma (OAG), ocular hypertension, sponsored by Nicox S.A.. Started Jun 2020; status: completed.
02
Drugs
NCX 470
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT04445519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04445519.